NVP 231

Research use only, not for human use.

NVP-231 is a potent, specific, and reversible CerK inhibitor(IC50=12±2 nM) that competitively inhibits binding of ceramide to CerK.

NVP-231 is a potent, specific, and reversible CerK inhibitor(IC50=12±2 nM) that competitively inhibits binding of ceramide to CerK.

Cell Viability Assay Cell Line:MCF-7 cells; NCI-H358 cells Concentration:0 nM, 10 nM, 100 nM, 300 nM, 500 nM, 1000 nM Incubation Time:48 hours Result:Reduced MCF-7 cells and NCI-H358 cells in a concentration manner. Apoptosis Analysis Cell Line:MCF-7 cells; NCI-H358 cells Concentration:1000 nM Incubation Time:24-72 hours Result:Increases caspase-3 and caspase-9 cleavage in MCF-7?and NCI-H358 cells.Western Blot Analysis Cell Line:MCF-7 cells; NCI-H358 cells Concentration:0 nM, 100 nM, 300 nM, 500 nM Incubation Time:24 hours Result:Decreased p-cyclin B1, p-CDK1 as a concentration manner.

——

NVP231 | NVP 231 | NVP-231

MAPK/ERK Signaling

ERK

CERK

Cancer

——

362003-83-6

431.55

C25H25N3O2S

>98% (HPLC)

Soluble in DMSO

O=C(C1(C2)C[C@H]3C[C@@H]2C[C@H](C3)C1)NC4=CC=C5N=C(NC(C6=CC=CC=C6)=O)SC5=C4

N -[2-(Benzoylamino)-6-benzothiazolyl]tricyclo[3.3.1.13,7]decane-1-carboxamide

(-20℃)

With Ice Pack

≥ 2 years